Tibra Equities Europe’s MacroGenics MGNX Stock Holding History

Tibra Equities Europe’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-14,800	Closed	-$251K	–	285
2019 Q2	$251K	Buy	+14,800	New	+$254K	0.02%	220

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Tibra Equities Europe's MGNX Position: Q3 2019 in Review

Tibra Equities Europe sold out of MacroGenics (MGNX) in Q3 2019, closing a stake of 14,800 shares — an estimated $251K sold.

Tibra Equities Europe first reported a position in MGNX in Q2 2019 and held it in 1 quarter. The position peaked at $251K in Q2 2019. 127 funds tracked by Wall St. Rank hold MGNX as of Q3 2019.

Tibra Equities Europe reported no remaining MacroGenics position as of Q3 2019 after selling out during the quarter.
Tibra Equities Europe sold 14,800 MacroGenics shares in Q3 2019, an estimated $251K.
Tibra Equities Europe first reported a position in MacroGenics in Q2 2019 and held it in 1 quarter.
Tibra Equities Europe's MacroGenics position peaked at $251K in Q2 2019.
127 funds tracked by Wall St. Rank held MacroGenics as of Q3 2019.

Based on Tibra Equities Europe's 13F filing for Q3 2019, filed 4 Nov 2019.